The present disclosure generally relates to therapeutic nanoparticles. Exemplary nanoparticles disclosed herein may include about 10 to about 70 weight percent of biocompatible polymers such as a di-block polymer (for example, poly(lactic)acid and polyethylene glycol or poly(lactic)-co-poly (glycolic) acid and poly(ethylene)glycol), about 5 to about 50 weight percent glyceride (for example, a monoglyceride, a diglyceride, or a triglyceride), and about 0.1% to about 40% weight percent therapeutic agent (for example, docetaxel or bortezomib).
